Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,296.40
(
0.68%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.44
(
-0.21%
)
Bitcoin
74,132.39
(
0.26%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: palindromy post# 75086

Friday, 03/27/2009 6:34:09 AM

Friday, March 27, 2009 6:34:09 AM

Post# of 257253

TEVA NVS MNTA: Based on the same principle, we can argue that if Teva loses, then the FDA should not approve Copaxone because a court has found that Novartis did not steal enough important data and hence the copy cannot be exact.

Huh? Have you missed the reason that NVS is partnered with MNTA on generic Lovenox and generic Copaxone?


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now